secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001193125-24-041504
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology appoints Caroline Germa as CMO; Sergio Santillana resigns
------------------------------------------------------------------------

- Sergio Santillana resigns as CMO effective Feb 29, 2024; will consult through Dec 31, 2024 at $500/hour.
- Caroline Germa, M.D., appointed CMO effective Feb 29, 2024; brings 25+ years pharma experience.
- Dr. Germa previously EVP & CMO at Transcenta, senior roles at AstraZeneca, BMS, Novartis.
- Focus on advancing IK-930 (Hippo pathway) and IK-595 (RAS/RAF mutant cancers) Phase I programs.
- Company on track for clinical update in second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524041504/0001193125-24-041504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524041504/d774502d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-041504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer